These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17477093)

  • 1. [Fibrates and markers of inflammation].
    Broncel M
    Pol Merkur Lekarski; 2007 Jan; 22(127):58-61. PubMed ID: 17477093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.
    Zambon A; Gervois P; Pauletto P; Fruchart JC; Staels B
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):977-86. PubMed ID: 16424352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nonlipid effects of fibrates].
    Celińska-Löwenhoff M; Undas A
    Przegl Lek; 2004; 61(2):99-101. PubMed ID: 15230150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia.
    Isma N; Barani J; Mattiasson I; Lindblad B; Gottsäter A
    Angiology; 2008; 59(5):542-8. PubMed ID: 18388063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease.
    Cheng AY; Leiter LA
    Diabetes Obes Metab; 2008 Sep; 10(9):691-8. PubMed ID: 17593234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inflammatory markers and cytokines in cardiovascular disease].
    Ogiwara F; Takahashi M; Ikeda U
    Rinsho Byori; 2004 Aug; 52(8):686-92. PubMed ID: 15478624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arterial stiffness and inflammatory response to psychophysiological stress.
    Ellins E; Halcox J; Donald A; Field B; Brydon L; Deanfield J; Steptoe A
    Brain Behav Immun; 2008 Aug; 22(6):941-8. PubMed ID: 18316176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
    Broncel M; Balcerak M; Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
    Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential use of PPARalpha agonists as immunosuppressive agents.
    Cunard R
    Curr Opin Investig Drugs; 2005 May; 6(5):467-72. PubMed ID: 15912959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of influenza vaccine on markers of inflammation and lipid profile.
    Tsai MY; Hanson NQ; Straka RJ; Hoke TR; Ordovas JM; Peacock JM; Arends VL; Arnett DK
    J Lab Clin Med; 2005 Jun; 145(6):323-7. PubMed ID: 15976761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects.
    Ye HJ; Zhao SP
    Med Hypotheses; 2006; 66(3):495-500. PubMed ID: 16289368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular mechanism of action of the fibrates].
    Fruchart JC; Duriez P; Staels B
    J Soc Biol; 1999; 193(1):67-75. PubMed ID: 10851558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia.
    Ye P; Li JJ; Su G; Zhang C
    Clin Chim Acta; 2005 Jun; 356(1-2):229-32. PubMed ID: 15936324
    [No Abstract]   [Full Text] [Related]  

  • 18. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease.
    Karadag F; Kirdar S; Karul AB; Ceylan E
    Eur J Intern Med; 2008 Mar; 19(2):104-8. PubMed ID: 18249305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
    Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):39-46. PubMed ID: 17717290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.